Clinical trialsCompany release

NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma

🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026

NeOnc Technologies says its single-arm, 24-patient study of intranasal NEO100 met its primary endpoint, though the data are not from a locked database and no control arm was used.

NeOnc Technologies (NASDAQ: NTHI) has issued a corporate presentation covering its two brain-tumour candidates: intranasal NEO100 and oral NEO212. The deck, dated 18 November 2026, highlights results from a Phase 2a study of NEO100 in recurrent IDH1-mutant grade III-IV glioma.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Neonc Technologies Holdings, Inc. ↗

Article written by VigiEye from the official source (Neonc Technologies Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.